Literature DB >> 3312932

Primidone crystalluria following overdose. A report of a case and an analysis of the literature.

D F Lehmann1.   

Abstract

Seven cases of crystalluria following primidone overdose have been reported since the 1950s. An eighth case of primidone crystalluria following overdose is presented. Because of low aqueous solubility (600 mg/L at 37 degrees C) which is directly proportional to temperature, any factor increasing renal excretion of unchanged primidone predisposes to crystal formation. Renal clearance is dependent on dosage because of negligible protein binding, zero-order conversion to phenobarbitone (phenobarbital) and first-order conversion to phenylethylmalonamide. Therapy with other anticonvulsants known to induce the metabolism to phenobarbitone does not appear to be protective against crystalluria in overdose situations. The critical serum primidone concentration for crystalluria presence seems to be 80 mg/L. There is evidence for nephrotoxicity of the crystals themselves if formed in vivo (actual crystal presence during voiding). The chemical phenomenon of supersaturation of a solution is protective against in vivo crystal formation with subsequent nephrotoxicity. Vigorous hydration to augment elimination and to lessen the propensity for renal toxicity is recommended.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312932     DOI: 10.1007/BF03259955

Source DB:  PubMed          Journal:  Med Toxicol Adverse Drug Exp        ISSN: 0113-5244


  11 in total

1.  Acute primidone overdosage with massive crystalluria.

Authors:  I V Cate JC; R Tenser
Journal:  Clin Toxicol       Date:  1975       Impact factor: 4.467

2.  Acute primidone intoxication.

Authors:  J Brillman; B B Gallagher; R H Mattson
Journal:  Arch Neurol       Date:  1974-03

3.  Chemical analysis of massive crystalluria following primidone overdose.

Authors:  D N Bailey; P I Jatlow
Journal:  Am J Clin Pathol       Date:  1972-11       Impact factor: 2.493

4.  Primidone kinetics: effects of concurrent drugs and duration of therapy.

Authors:  J C Cloyd; K W Miller; I E Leppik
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

5.  Primidone intoxication and massive crystalluria.

Authors:  C R Turner
Journal:  Clin Pediatr (Phila)       Date:  1980-10       Impact factor: 1.168

6.  Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration.

Authors:  B B Gallagher; I P Baumel; R H Mattson
Journal:  Neurology       Date:  1972-11       Impact factor: 9.910

7.  Intoxication with primidone: continuous monitoring of serum primidone and its metabolites during forced diuresis.

Authors:  I Lagenstein; H J Sternowsky; E Iffland; E Blaschke
Journal:  Neuropadiatrie       Date:  1977-05

8.  Disposition of primidone in man: an example of autoinduction of a human enzyme system?

Authors:  J W Huisman
Journal:  Pharm Weekbl       Date:  1969-07-04

9.  Coma and crystalluria: a massive primidone intoxication treated with haemoperfusion.

Authors:  A N van Heijst; W de Jong; R Seldenrijk; A van Dijk
Journal:  J Toxicol Clin Toxicol       Date:  1983-06

10.  Acute phenytoin and primidone intoxication: a pharmacokinetic analysis.

Authors:  G R Matzke; J C Cloyd; R J Sawchuk
Journal:  J Clin Pharmacol       Date:  1981 Feb-Mar       Impact factor: 3.126

View more
  4 in total

1.  The appearance of urine as a diagnostic aid.

Authors:  N Murphy
Journal:  Arch Emerg Med       Date:  1989-12

Review 2.  The risk-benefit ratio of anticonvulsant drugs.

Authors:  M J Eadie
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 3.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 4.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.